Bradykinin-Mediated Angioedema Induced by Drugs

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Allergy and Immunology

Background:

• Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are widely used for cardiovascular disease prevention.
• These drugs can induce bradykinin (BK)-mediated angioedema (AE), a potentially fatal swelling caused by increased vascular permeability.
• Unlike hereditary angioedema (HAE), drug-induced AE lacks approved diagnostic tools and treatments.

Purpose of the Study:

• To review the molecular mechanisms of drug-induced BK-mediated angioedema.
• To highlight the current unmet needs in the diagnosis and management of this adverse drug reaction.
• To provide physicians with essential knowledge for understanding and managing potentially life-threatening drug-induced AE.

Main Methods:

• Literature review on drug-induced angioedema.
• Discussion of molecular mechanisms involving bradykinin.
• Analysis of current diagnostic and therapeutic gaps.

Main Results:

• ACEIs and ARBs are common culprits for BK-mediated AE.
• Other drugs like DPP-IV inhibitors and neprilysin inhibitors can also cause AE.
• Insufficient data exists regarding AE prevention and management.

Conclusions:

• Drug-induced angioedema is a serious adverse effect requiring better understanding and management strategies.
• There is a critical need for approved diagnostic tools and specific treatments for drug-induced AE.
• Further research into molecular mechanisms and prevention is essential.